Genesis Therapeutics is a biotech company pioneering AI technologies to create medicines for patients with severe and unmet medical needs.
Genesis invents and deploys breakthrough AI techniques to discover and develop drugs both internally as well as in select partnerships.
Genesis was founded in 2019 by Evan Feinberg alongside with Ben Sklaroff and James Schaeffer. The company is headquartered in headquartered in Burlingame, CA, with a fully integrated laboratory in San Diego
Genesis is unifying AI and biotechnology to discover novel and breakthrough treatments for patients with severe and devastating conditions. The company is unique in its groundbreaking deep learning technology, its synergy of machine learning with biophysical simulation and its pairing of AI with extensive biotech/pharma expertise.
Genesis’ internal pipeline programs have been enabled by the GEMS AI platform, which leverages proprietary, field-leading, generative and predictive AI methods to produce novel molecules and make rapid, accurate predictions of properties such as potency, selectivity, and ADMET.
Genesis' GEMS is uniquely capable of identifying and enabling drug candidates for challenging, data-poor, and previously undruggable targets, thereby allowing Genesis to make progress towards breakthrough treatments with the potential for transformative impact across significant and underserved patient populations.
Genesis is backed by T. Rowe Price Associates, Andreessen Horowitz, Fidelity Management & Research Company, BlackRock, Rock Springs Capital, NVentures, Menlo Ventures, Radical Ventures, and others. The company raised $200M in an oversubscribed Series B round on Aug 21, 2023. This brings Genesis' total funding to $280.1M to date.